Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...

Shares of Xenon Pharmaceuticals (XENE) have gained approximately 20% over the past three months, primarily driven by positive top-line data from the X-TOLE2 study evaluating its lead candidate, ...

Xenon Pharmaceuticals (XENE) has drawn attention after its share price moved 37.1% over the past week and about 39% over the past month, prompting investors to reassess the story behind the stock. The ...

Check out some of the companies making the biggest midday moves: Oil stocks — Oil stocks briefly traded higher as the commodity surged as the Iran War showed no sign of abating. U.S. crude briefly ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

Xenon Pharmaceuticals is conducting five additional Phase 3 studies for azetukalner across epilepsy and neuropsychiatric indications. These developments underscore the growing interest in Xenon’s lead ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006 ...

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...

Xenon Pharmaceuticals Inc. XENE-Q stock soared Monday after the Canadian drug developer reported better-than-expected results from a late-stage human trial for its epilepsy treatment. Burnaby, ...

Rick Bishop got a black Labrador named Sailor in 2017 to help deal with the epileptic seizures he had multiple times daily. Sailor hasn’t had much to do since the rural Pennsylvania-based retiree ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.